Novel Coronavirus (SARS-CoV-2/COVID-19)
The AHA, American Medical Association, American Society of Health-System Pharmacists, and United States Pharmacopeia convened a virtual summit to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.
The National Institutes of Health announced clinical trials to investigate the safety and efficacy of a synthetic antibody therapy in COVID-19 patients.
The Centers for Medicare & Medicaid Services will allow health insurers to offer premium reductions for individuals with 2020 coverage in the individual and small group markets when consistent with state law, the agency announced.
The Department of Health and Human Services released specifications for reporting certain COVID-19 laboratory data as required by the Coronavirus Aid, Relief, and Economic Security Act.
The U.S. District Court for the Southern District of New York ruled against the Department of Labor regarding its regulations related to certain expanded paid leave authorized by the Families First Coronavirus Response Act.
President Trump Aug. 3 signed an executive order on “improving rural health and telehealth access,” with directives to: launch a new payment model for rural health care; develop and implement a strategy to improve rural health care infrastructure.
Leading healthcare groups convened a summit, “Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security,” on July 27-31 to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.
The pandemic has given high-risk patients cause for concern about returning to health care providers for routine care. The impact of this medical distancing won’t be fully understood for some time but, in the meantime, hospitals and health care systems face yet another significant hurdle in a year…
The National Institutes of Health’s Rapid Acceleration of Diagnostics initiative awarded $248.7 million in contracts to produce four new laboratory tests and three new point-of-care tests to detect SARS-CoV-2.
A Renewed Call to Dare All for Our Country